Repair & Recovery
BPC-157 Injection
A stable peptide fragment studied in preclinical research for its role in tissue repair and gut lining integrity — frequently used off-label for soft-tissue recovery.
This is a compounded preparation made by a licensed pharmacy. It is not FDA-approved, and it is prescribed only when a licensed provider determines it is appropriate for you.
Already know this is what you want? The second option books the appointment straight away. Not sure yet? See the labs first.
Your consult is free. We will not prescribe this, or anything, before a clinician has spoken with you. Final cost depends on the form and dose prescribed.
Mechanism
Support repair, don't mask it.
BPC-157 (Body Protection Compound-157) is a synthetic peptide fragment derived from a protein found in gastric juice. In animal and cell-based studies, it has been associated with increased blood vessel formation and collagen activity at sites of tissue damage.
It is most often used by patients recovering from soft-tissue injuries — tendons, ligaments and the gut lining — rather than as a general wellness peptide.
It is typically prescribed for a defined cycle tied to an injury or recovery window rather than as an ongoing daily therapy.
Protocol
How treatment usually runs.
A typical schedule. Yours is set by your clinician, and adjusted as you go.
| Phase | Weeks | Typical | Purpose |
|---|---|---|---|
| Start | 1–2 | Low dose once daily | Injected near the affected area or subcutaneously as directed. |
| Build | 3–6 | Standard dose once or twice daily | Adjusted based on response and tolerance. |
| Taper / Reassess | 7–8 | Continued or tapered | Most cycles run 4–8 weeks before a break is reviewed with your provider. |
What to expect
Honestly, over time.
Early changes
Some patients report reduced localized discomfort.
Continued recovery
Reported improvement is gradual and varies by injury type.
Cycle review
Most protocols are reassessed at 6–8 weeks rather than continued indefinitely.
Evidence
What the research shows.
Most evidence for BPC-157 comes from animal and laboratory studies rather than large controlled human trials. Mechanistic research suggests a role in angiogenesis and tissue repair pathways, but rigorous human clinical data remain limited.
Results vary. Clinical trial results apply only to the FDA-approved branded medication specifically identified and do not apply to compounded medications. All medications must be prescribed by a licensed provider based on medical necessity.
Safety and eligibility
Your consult and labs screen for all of the following.
- Do not use if you have a history of cancer or an active malignancy — BPC-157 is studied for promoting blood vessel and tissue growth, which is a serious consideration in anyone with a cancer history; discuss this directly with your provider before starting.
- Tell your provider about any autoimmune condition, pregnancy or plans to become pregnant, and all current medications.
- Common side effects include injection-site redness, irritation or swelling, and mild fatigue.
- Not FDA-approved for this use — prescribed at your provider's discretion.
FAQ
BPC-157 Injection questions.
BPC-157 is a peptide studied mainly for its potential role in soft-tissue and gut-lining repair. It's typically prescribed for a defined recovery window rather than as a long-term daily supplement.
It's generally injected subcutaneously once or twice daily for a cycle of about 4 to 8 weeks, with dose and duration set by your provider based on your injury and response.
It isn't appropriate for patients with a history of cancer, since it's studied for promoting tissue and blood vessel growth. Your provider will review your full medical history before prescribing.
Related
Often part of the same plan.
BPC-157 + TB-500 Injection (Wolverine Stack)
Subcutaneous injection
BPC-157 / KPV / TB-500 Injection (Repair & Recovery Stack)
Subcutaneous injection
